Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-152 |
Sentence |
denotes |
A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. |
T2 |
153-164 |
Sentence |
denotes |
OBJECTIVES: |
T3 |
165-344 |
Sentence |
denotes |
To identify and quantify resource required and associated costs for implementing TNF-α inhibitor (TNFi) drug level and anti-drug antibody (ADAb) tests in UK rheumatology practice. |
T4 |
345-353 |
Sentence |
denotes |
METHODS: |
T5 |
354-545 |
Sentence |
denotes |
A microcosting study, assuming the UK National Health Service perspective, identified the direct medical costs associated with providing TNFi drug level and ADAb testing in clinical practice. |
T6 |
546-826 |
Sentence |
denotes |
Resource use and costs per patient were identified via four stages: identification of a patient pathway with resource implications; estimation of the resources required; identification of the cost per unit of resource (2015 prices); and calculation of the total costs per patient. |
T7 |
827-938 |
Sentence |
denotes |
Univariate and multiway sensitivity analyses were performed using the variation in resource use and unit costs. |
T8 |
939-947 |
Sentence |
denotes |
RESULTS: |
T9 |
948-1149 |
Sentence |
denotes |
Total costs for TNFi drug level and concurrent ADAb testing, assessed using ELISAs on trough serum levels, were £152.52/patient (range: £147.68-159.24) if 40 patient samples were tested simultaneously. |
T10 |
1150-1309 |
Sentence |
denotes |
For the base-case analysis, the pre-testing phase incurred the highest costs, which included booking an additional appointment to acquire trough blood samples. |
T11 |
1310-1470 |
Sentence |
denotes |
The additional appointment was the key driver of costs per patient (67% of the total cost), and labour accounted for 10% and consumables 23% of the total costs. |
T12 |
1471-1576 |
Sentence |
denotes |
Performing ELISAs once per patient (rather than in duplicate) reduced the total costs to £133.78/patient. |
T13 |
1577-1588 |
Sentence |
denotes |
CONCLUSION: |
T14 |
1589-1681 |
Sentence |
denotes |
This microcosting study is the first assessing the cost of TNFi drug level and ADAb testing. |
T15 |
1682-1842 |
Sentence |
denotes |
The results could be used in subsequent cost-effectiveness analyses of TNFi pharmacological tests to target treatments and inform future policy recommendations. |
T1 |
0-152 |
Sentence |
denotes |
A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. |
T2 |
153-164 |
Sentence |
denotes |
OBJECTIVES: |
T3 |
165-344 |
Sentence |
denotes |
To identify and quantify resource required and associated costs for implementing TNF-α inhibitor (TNFi) drug level and anti-drug antibody (ADAb) tests in UK rheumatology practice. |
T4 |
345-353 |
Sentence |
denotes |
METHODS: |
T5 |
354-545 |
Sentence |
denotes |
A microcosting study, assuming the UK National Health Service perspective, identified the direct medical costs associated with providing TNFi drug level and ADAb testing in clinical practice. |
T6 |
546-826 |
Sentence |
denotes |
Resource use and costs per patient were identified via four stages: identification of a patient pathway with resource implications; estimation of the resources required; identification of the cost per unit of resource (2015 prices); and calculation of the total costs per patient. |
T7 |
827-938 |
Sentence |
denotes |
Univariate and multiway sensitivity analyses were performed using the variation in resource use and unit costs. |
T8 |
939-947 |
Sentence |
denotes |
RESULTS: |
T9 |
948-1149 |
Sentence |
denotes |
Total costs for TNFi drug level and concurrent ADAb testing, assessed using ELISAs on trough serum levels, were £152.52/patient (range: £147.68-159.24) if 40 patient samples were tested simultaneously. |
T10 |
1150-1309 |
Sentence |
denotes |
For the base-case analysis, the pre-testing phase incurred the highest costs, which included booking an additional appointment to acquire trough blood samples. |
T11 |
1310-1470 |
Sentence |
denotes |
The additional appointment was the key driver of costs per patient (67% of the total cost), and labour accounted for 10% and consumables 23% of the total costs. |
T12 |
1471-1576 |
Sentence |
denotes |
Performing ELISAs once per patient (rather than in duplicate) reduced the total costs to £133.78/patient. |
T13 |
1577-1588 |
Sentence |
denotes |
CONCLUSION: |
T14 |
1589-1681 |
Sentence |
denotes |
This microcosting study is the first assessing the cost of TNFi drug level and ADAb testing. |
T15 |
1682-1842 |
Sentence |
denotes |
The results could be used in subsequent cost-effectiveness analyses of TNFi pharmacological tests to target treatments and inform future policy recommendations. |